While further, multi-institutional studies are needed to better characterize treatment outcomes after LITT in patients with IDH1/2 mutant glioma and to elucidate risk factors for progression, the findings in this study suggest that LITT may be an effective treatment option for this molecular subtype. This evidence concerns the gene IDH1 and central nervous system cancer.